e21068 Background: Docetaxel is a standard second line treatment in advanced NSCLC,
but the treatment effect is limited. Previous studies, such as REVEL, demonstrated that anti …

Background Antiangiogenic therapy combined with PD-1/PD-L1 inhibitors has shown
excellent efficacy in advanced NSCLC pts. The ALTER 0303 trial showed that anlotinib …

Abstract Background On May 8, 2018, the China National Medical Products Administration
(NMPA) approved anlotinib, an orally administered anti‐angiogenesis inhibitor, for the …

Background This real‐world study assessed the efficacy and toxicity of anlotinib as salvage
treatment in Chinese patients with advanced non‐small cell lung cancer (NSCLC). Methods …

Background The aim of this study was to investigate the efficacy and safety of anlotinib for
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …

Methods Patients with unresectable stage IIIB to IV NSCLC who had received anlotinib were
enrolled in two cohorts, 1 st line anlotinib monotherapy (cohort A) and≥ 2 nd line anlotinib …

Background The evidence of combined therapies of multi-target agents in first-line treatment
of advanced non-small cell lung cancer (NSCLC) was limited. This study aimed to evaluate …

Purpose: In this meta-analysis and systemic review, we focused on the effectiveness and
safety of anlotinib in patients with advanced non-small cell lung cancer (NSCLC). Methods …

Background. Anlotinib hydrochloride is an oral small molecule inhibitor of multiple tyrosine
kinases, and it has been approved as a third-line therapy for patients with advanced non …

Purpose: To evaluate the efficacy and safety of anlotinib in the third-line treatment of
advanced non-small cell lung cancer (NSCLC) and assess its effect on the patient quality of …